Breast cancer and HCC patients positive for DRD1 expression have a poor prognosis [10, 11], and dopamine receptor inhibitors can destroy tumor cells by terminating the self-renewal of tumor stem cells [12]; moreover, they can also inhibit AKT signaling pathways, leading to suppression of breast tumor growth [13]. Here, DRD1 is linked to hepatocellular carcinoma.